Lung Cancer and Idiopathic Pulmonary Fibrosis Clinical Trial
— K-FPIOfficial title:
Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization
Verified date | February 2018 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers. The cases are recovered retrospectively from the records of the pulmonology and pathology departments of our various partners.
Status | Enrolling by invitation |
Enrollment | 100 |
Est. completion date | February 2020 |
Est. primary completion date | February 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Lung carcinoma - Idiopathic pulmonary fibrosis Exclusion Criteria: - No tumor sample available |
Country | Name | City | State |
---|---|---|---|
France | Hopital BICHAT-CLAUDE BERNARD | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Molecular profile of IPF-associated lung carcinomas | Next generation sequencing of carcinomas with Ion S5 XL sequencer and Oncomineā¢ Comprehensive Panel | 1 month / 8 samples | |
Secondary | Pathological characterization of lung carcinomas | Histological classification of carcinomas and immunohistochemistry with lineage markers | 1 month / 8 samples |